Torii Pharmaceutical Co., Ltd.
Torii Pharmaceutical Co., Ltd. (TRXPF) Financial Performance & Income Statement Overview
Analyze Torii Pharmaceutical Co., Ltd. (TRXPF) financial statements (income, balance sheet, and cash flow) across both yearly and quarterly periods.
Torii Pharmaceutical Co., Ltd. (TRXPF) Income Statement & Financial Overview
Review Torii Pharmaceutical Co., Ltd. TRXPF income statement with detailed quarterly and annual figures.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| Revenue | $14.68B | $17.09B | $15.02B | $14.86B |
| Cost of Revenue | $8.06B | $12.08B | $8.23B | $8.21B |
| Gross Profit | $6.62B | $5.02B | $6.79B | $6.64B |
| Gross Profit Ratio | $0.45 | $0.29 | $0.45 | $0.45 |
| R&D Expenses | $677.00M | $628.00M | $833.00M | $831.00M |
| SG&A Expenses | $4.24B | $2.05B | $4.44B | $4.05B |
| Operating Expenses | $4.92B | $2.88B | $5.27B | $4.89B |
| Total Costs & Expenses | $12.98B | $14.96B | $13.51B | $13.10B |
| Interest Income | $113.00M | $0.00 | $93.00M | $82.00M |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 |
| Depreciation & Amortization | $98.00M | $102.00M | $99.00M | $94.00M |
| EBITDA | $1.95B | $2.24B | $1.79B | $1.82B |
| EBITDA Ratio | $0.13 | $0.13 | $0.12 | $0.12 |
| Operating Income | $1.70B | $2.14B | $1.52B | $1.76B |
| Operating Income Ratio | $0.12 | $0.13 | $0.10 | $0.12 |
| Other Income/Expenses (Net) | $150.00M | -$81.00M | $173.00M | $58.00M |
| Income Before Tax | $1.85B | $2.06B | $1.69B | $1.82B |
| Income Before Tax Ratio | $0.13 | $0.12 | $0.11 | $0.12 |
| Income Tax Expense | $462.00M | $539.00M | $388.00M | $474.00M |
| Net Income | $1.39B | $1.52B | $1.30B | $1.34B |
| Net Income Ratio | $0.09 | $0.09 | $0.09 | $0.09 |
| EPS | $49.48 | $53.96 | $46.39 | $47.78 |
| Diluted EPS | $49.48 | $53.96 | $46.39 | $47.78 |
| Weighted Avg Shares Outstanding | $28.11M | $28.11M | $28.11M | $28.11M |
| Weighted Avg Shares Outstanding (Diluted) | $28.11M | $28.11M | $28.11M | $28.11M |
The company's financials show resilient growth, with revenue advancing from $14.86B in Q2 2024 to $14.68B in Q1 2025. Gross profit remained healthy with margins at 45% in Q1 2025 compared to 45% in Q2 2024. Operating income hit $1.70B last quarter, sustaining a consistent 12% margin. Changes in R&D and SG&A spending did not hinder EBITDA, which stood at $1.95B. Net income dropped to $1.39B, while earnings per share reached $49.48. Strong cost management and operational efficiency kept profitability intact, underlining the company's stable and competitive market performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan